Drug · PCSK9 / LDL-C · PCSK9 / LDL-C · Verified drug
Alirocumab (Praluent) structure · mechanism
Alirocumab (Praluent) 2D structure
- Role
- Drug
- Mechanism class
- PCSK9 / LDL-C
- Parent scaffold
- PCSK9-binding macrocyclic peptide pharmacophore
- Structure source
- Catalog seed (external identifier on file)
- ChEMBL ID
- CHEMBL1743034
Hand-written analysis
Mechanism
알리로쿠맙은 순환 PCSK9를 중화하는 완전 인간 IgG1 항체입니다. LDL 수용체 분해가 줄면 LDL-C가 떨어집니다. 에볼로쿠맙과 표적은 같고 이소타입·투약이 다릅니다.
Medicinal chemistry
소분자가 아닙니다. siRNA·경구 매크로사이클과 모달리티가 갈립니다.
Indication · context
가족성 고콜레스테롤·죽상경화 고위험. PCSK9 허브의 항체 축입니다.
SMILES
CC(C)C[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)OTags
Related compounds
Comparisons · briefs
External IDs · BioMoa
StructureMoa is a chemical-structure exploration tool. Structural similarity, clustering, and SAR relationships are intended for research exploration and do not establish shared potency, selectivity, safety, efficacy, or clinical performance.